New insights into the role of age and carcinoembryonic antigen in the prognosis of colorectal cancer

British Journal of Cancer

Volumn 98, Issue 2, 2008, Pages 328-334

  Gobbi, P G ^a   Valentino, F ^a   Berardi, E ^a   Tronconi, C ^a   Brugnatelli, S ^a   Luinetti, O ^a   Moratti, R ^a   Corazza, G R ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Age; CEA; Colorectal cancer; Relative survival; Staging

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; FEMALE; FOLLOW UP; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RECTUM CARCINOMA;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; CARCINOEMBRYONIC ANTIGEN; CARCINOMA; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 38549141327     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604114     Document Type: Article

References (51)

1. American Joint Committee on Cancer (2002) Cancer Staging Manual, 6th edn, pp 113-119. Springer-Verlag: New York
2. Andre T, Louvet C, Maindrault-Goebel F, Couteau C, Mabro M, Lotz JP, Gilles-Amar V, Krulik M, Carola E, Izrael V, De Gramont A (1999) CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated and metastatic colorectal cancer. GERCOR. Eur J Cancer 35: 1343-1347
3. Armitage P, Berry G (1987) Statistical Methods in Medical Research, 2nd edn, Oxford: Blackwell Scientific Publication, pp 421-437
4. Astler VB, Coller FA (1954) The prognostic significance of direct extension of carcinoma of the colon and the rectum. Ann Surg 139: 707-711
5. Cai SR, Zheng S, Zhang SZ (2005) Multivariate analysis of prognostic factors in colorectal cancer. Zhonghua Zhong Liu Za Zhi 27: 483-485
6. Cerottini JP, Caplin S, Pampallona S, Givel JC (1999) Prognostic factors in colorectal cancer. Oncol Rep 6: 409-414
7. Chen CC, Yang SH, Lin JK, Lin TC, Chen WS, Jiang JK, Wang LW (2005) Is it reasonable to add preoperative level of CEA and CA19-9 to staging for colorectal cancer? J Surg Res 124: 169-174
8. Choi JS, Min JS (1997) Significance of postoperative serum level of carcinoembryonic antigen (CEA) and actual half life of CEA in colorectal cancer patients. Yonsei Med J 38: 1-7
9. Chung YE, Eu KW, Machin D, Ho JM, Leong AF, Ho YU, Seow-Choen F (1998) Young age is not a poor prognostic factor in colorectal cancer. Br J Surg 85: 1255-1259
10. Compton C, Fenoglio-Praser CM, Peltigrew N, Peter Fielding L (2000) American Joint Committee on Cancer Prognostic Factors Consensus Conference. Colorectal Cancer Group. Cancer 88: 1739-1757
11. Cox DR (1972) Regression models and life tables. J R Stat Soc 34: 187-220
12. Crawford NPS, Colliver DW, Galandiuk S (2003) Tumor markers and colorectal cancer: utility in management. J Surg Oncol 84: 239-248
13. Crocetti E, Barchielli A, Buiatti E, Castiglione G, Zappa M (1996) Colorectal cancer survival - population-based rates in the province of florence. Eur J Cancer Prev 5: 189-195
14. D'Eredita G, Serio G, Neri Y, Polizzi RA, Barberio G, Losacco T (1996) A survival regression analysis of prognostic factors in colorectal cancer. Aust NZ J Surg 66: 445-451
15. De Gramont A, Bosset JF, Milan C, Rougier P, Bouche O, Etienne PL, Morvan F, Louvet C, Guillot T, François E, Bedenne L (1997) Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French Intergroup study. J Clin Oncol 15: 808-815
16. De Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyyer G, Papamichael D, Le Bali N (2000) Leucovorin and fluorouracil with or without oxaliplatin as firstline treatment in advanced colorectal cancer. J Clin Oncol 16: 2938-2947
17. Dukes CE (1940) Cancer of the rectum: an analysis of 1000 cases. J Pathol Bacteriol 50: 527-539
18. Fietkau R, Zetti H, Klocking S, Kundt G (2004) Incidence, therapy and prognosis of colorectal cancer in different age groups. A population-based cohort study of the Rostock Cancer Registry. Strahlenther Onkol 180: 478-487
19. Frank RE, Saclarides TJ, Leurgans S, Speziale NJ, Drab EA, Rubin DB (1995) Tumor angiogenesis as a predictor of recurrence and survival in patients with node-negative colon cancer. Ann Surg 222: 695-699
20. Gasser A, Isaak B, Maibach R, Ruchti C, Wagner HE, Nothiger E (1992) Staging and prognosis of colorectal carcinoma. Schweiz Med Wochenschr 122: 1356-1362
21. Herrera MA, Chu TM, Holyoke ED (1976) Carcinoembryonic antigen (CEA) as a prognostic and monitoring test in clinically complete resection of colorectal carcinoma. Ann Surg 183: 5-9
22. Heys SD, Walker LG, Deehan DJ, Eremin OE (1998) Serum albumin: a prognostic indicator in patients with colorectal cancer. J R Coll Surg Edinb 43: 163-168
23. Ito K, Hibi K, Ando H, Hidemura K, Yamazaki T, Akiyama S, Nakao A (2002) Usefulness of analytical CEA doubling time and half-life time for overlooked synchronous metastases in colorectal carcinoma. Jpn J Clin Oncol 32: 54-58
24. Janssen-Heijnen ML, Houterman S, Lemmens VE, Louwman MW, Maas HA, Coeberg JW (2005) Prognostic impact of increasing age and comorbidity in cancer patients: a population-based approach. Clin Rev Oncol Hematol 55: 231-240
25. Kanellos I, Demetriades H, Zintzaras E, Mandrali A, Mantzoros I, Betsis D (2003) Incidence and prognostic value of positive peritoneal cytology in colorectal cancer. Dis Colon Rectum 46: 535-539
26. Kanellos I, Zacharakis E, Demetriades H, Christoforidis E, Kanellos D, Pramateftakis M-G, Betsis D (2006a) Value of carcinoembryonic antigen assay in predicting hepatic metastases, local recurrence, and survival after curative resection of colorectal cancer. Surg Today 36: 879-884
27. Kanellos I, Zacharakis E, Kanellos D, Pramateftakis M-G, Betsis D (2006b) Prognostic significance of CEA levels and positive cytology in peritonela washings in patients with colorectal cancer. Colorectal Dis 8: 436-440
28. Kanellos I, Zacharakis E, Kanellos D, Pramateftakis M-G, Tsahalis T, Altsitsiadis E, Betsis D (2006c) Prognostic significance of CEA levels and detection of CEA mRNA in draining venous blood in patients with colorectal cancer. J Surg Oncol 94: 3-8
29. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481
30. Korenaga D, Ueo H, Mochida K, Kusumoto T, Baba H, Tamura S, Moriguchi S, Sugimachi K (1991) Prognostic factors in Japanese patients with colorectal cancer: the significance of large bowel obstruction - univariate and multivariate analyses. J Surg Oncol 47: 188-192
31. Lagautriere F, Valvano L, Chaazl M, Benchimol D, Bernard JL, Bourgeon A, Richelme H (1998) Prognostic factors in colorectal cancer. Ann Ital Chir 69: 491-497
32. Latkauskas T, Rudinskaite G, Kurtinaitis J, Janciauskiene R, Tamelis A, Saladzinskas Z, Pawalkis D (2005) The impact of age on post-operative outcomes of colorectal cancer patients undergoing surgical treatment. BMC Cancer 5: 153-158
33. Louhimo J, Carpelan-Holmstrom M, Alfthan H, Stenman UH, Jarvinen HJ, Haglund C (2002) Serum HCG beta, CA72-4 and CEA are independent prognostic factors in colorectal cancer. Int J Cancer 101: 545-548
34. Machover D, Schwarzenberg L, Goldschmidt E, Tourani JM, Michalski B, Hayat M, Dorval T, Misset JL, Jasmin C, Maral R, Mathe G (1982) Treatment of advanced colorectal and gastric adenocarcinoma with 5-FU combined with high-dose folinic acid: a pilot study. Cancer Treat Rep 66: 1803-1807
35. Massacesi C, Pistilli B, Valeri M, Lippe P, Rocchi MB, Cellerino R, Piga A (2002) Predictors of short-term survival and progression to chemotherapy in patients with advanced colorectal cancer treated with 5-fluorouracil-based regimens. Am J Clin Oncol 25: 140-148
36. Matthes M, Lucas A, Boland R, Hirth V, Odenheimer G, Wieland D, Williams H, Eleazer GP (2004) Use of a questionnaire to screen for frailty in the elderly: an exploratory study. Aging Clin Exp Res 16: 34-40
37. Menin C, Scaini MC, De Salvo GL, Biscuola M, Quaggio M, Esposito G, Belluco C, Montagna M, Agata S, D'Andrea E, Nitti D, Amadori A (2006) Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. J Natl Cancer Inst 98: 285-288
38. Mitry E, Douillard J-Y, Van Cutsem E, Cunningham D, Magherini E, Mery-Mignard D, Awad L, Rougier P (2004) Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinitecan phase III trials. Ann Oncol 15: 1013-1017
39. Munemoto Y, Iida Y, Ohata K, Saito H, Fujisawa K, Kasahara Y, Mitsui T, Asada Y, Miura S (2004) Significance of postoperative adjuvant immunochemotherapy after curative resection of colorectal cancers: identification of responders incorporating the age factor. Oncol Rep 11: 623-635
40. Newland RC, Dent OF, Lyttle MN, Chapuls PH, Bokey EL (1994) Pathologic determinants of survival associated with colorectal cancer with lymph node metastases. A multivariate analysis of 579 patients. Cancer 78: 403-408
41. Payne JE, Meyer HJ (1997) Independently predictive prognostic variables after resection for colorectal carcinoma. Aust NZ J Surg 67: 849-853
42. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG (1977) Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 35: 1-39
43. Ponz de Leon M, Sant M, Micheli A, Sacchetti C, Di Gregorio C, Fante R, Zanghieri G, Melotti G, Gatta G (1992) Clinical and pathological prognostic indicators in colorectal cancer. Cancer 69: 626-635
44. Rapellino M, Piantino P, Pecchio F, Ruffini E, Cavallo A, Scappaticci E, Baldi S, Ciocia E, Pivetti S (1994) Disappearance curves of tumor markers after radical surgery. Int J Biol Markers 9: 33-37
45. Repetto L, Comandini D, Mammoliti S (2001) Life expectancy, comorbidity and quality of life: the treatment equation in the older cancer patients. Crit Rev Oncol Hematol 37: 147-152
46. Takahashi Y, Tucker SI, Kitadal Y, Koura AN, Bucana DC, Cleary KR, Ellis LM (1997) Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Arch Surg 132: 541-546
47. Tominaga T, Sakabe T, Koyama Y, Hamano K, Yasutomi M, Takahashi T, Kodaira S, Kato T, Ogawa N (1997) Prognostic factors for patients with colon or rectal carcinoma treated with resection only. Five-year follow-up report. Cancer 78: 403-408
48. Wanebo HJ, Rao B, Pinsky CM, Hoffman RG, Stearns M, Schwartz MK, Oettgen HF (1978) Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer. N Engl J Med 299: 448-451
49. Wang WS, Chen PM, Chiou TJ, Liu JH, Fan FS, Lin TC, Jiang JK, Yang SH, Chen PM (2000) Factors predictive of survival in patients with nodepositive colorectal cancer. Hepatogastroenterology 47: 1590-1594
50. Wolters U, Stutzer H, Keller HW, Schroder U, Pichlmaier H (1996) Colorectal cancer - a multivariate analysis of prognostic factors. Eur J Surg Oncol 22: 592-597
51. Yuste AL, Aparicio J, Segura A, Lopez-Tendero P, Girones R, Perez-Fidalgo JA, Diaz R, Calderero V (2003) Analysis of clinical prognostic factors for survival and time to progression in patients with metastatic colorectal cancer treated with 5-fluoruracil-based chemotherapy. Clin Colorectal Cancer 2: 231-234